Pfizer and BioNTech have presented positive results from their clinical trial in children between the ages of 5 and 11. Their COVID-19 vaccine is “safe,” elicits a “robust” immune response, and is “well-tolerated,” according to a press release.
People between the ages of 12 and 17 have been able to receive the COVID-19 vaccine since June 15. Currently, 69% of this age group has received their first dose. With the spread of the Delta variant, the question arises: should children under 12 be vaccinated? While the benefits of the COVID-19 vaccine for younger children are still being debated, Pfizer and BioNTech have just announced that their vaccine is safe for children between the ages of 5 and 11.
Pfizer states that the vaccine offers a robust immune response and is well-tolerated.
Pfizer and BioNTech announced, in a press release published on September 20, the positive results of their clinical trial conducted with 2,268 children between the ages of 5 and 11. Participants received two 10-microgram doses of the vaccine, 21 days apart. It is worth noting that the dose for children over 12 years of age is 30 micrograms.
